Organogenesis Holdings (NASDAQ: ORGO) has announced the publication of peer-reviewed trial results in the Journal of Wound Care (JWC) showing the clinical benefit of PuraPly AM for hard-to-treat diabetic foot ulcers (DFUs).
According to Organogenesis, PREPARE is a prospective, multicenter, randomized controlled trial evaluating PuraPly AM (PCMP) plus standard of care (SoC) compared to SoC alone in hard-to-heal diabetic foot ulcers. The results published in JWC demonstrate statistically significant improvements in wound closure at 12 weeks among patients treated with PuraPly AM plus SoC, providing clinical evidence supporting the use of PuraPly AM in one of the most costly and difficult-to-treat chronic wound populations.
In a statement, Patrick Bilbo, COO of Organogenesis, commented, “The PREPARE study adds to our large and growing body of data for PuraPly AM, including real-world evidence from registry and comparative effectiveness studies, and health economics and outcomes research. We expect this evidence to form the basis for future coverage decisions for PuraPly AM. Peer-reviewed data continues to differentiate us in a recalibrated market where Organogenesis is gaining share while competitors without comparable evidence are pivoting away from wound care or exiting the market altogether.”
